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INTRODUCTION
Estrogen affects the growth and differentiation of the repro-
ductive tissues as well as other metabolic processes by bind-
ing to the estrogen receptor (ER), that regulates the specific
gene expression in the target tissues. ER is a member of the
transcriptional activator family and requires a high mobility
group-1 (HMGB-1) for its full transcriptional activity (1).
HMGB-1 is the most abundant and the most prominent
member of the HMGB family. It is a ubiquitous and highly
conserved nonhistone chromosomal protein that is implicated
in transcription, replication and recombination as well as in
chromatin organization (2). In general, the HMGB-1 gene
appears to be tightly regulated and is expressed at the basal
level in most cells and tissues (3). The HMGB-1 expression
level is increased approximately 2-fold in proliferating tissues
as well as in actively dividing cells (4-6). A similar increase
has also been observed when estrogen responsive breast cancer
cells are treated with estrogen (7), and when synchronized
CHO cells progress from the G1 to S phase (8). Furthermore,
in the rat uterus, it was reported that HMGB-1 synthesis is
stimulated by an estrogen treatment (9). This suggests that
the intracellular levels of HMGB-1 may be an important reg-
ulatory factor for the action of ER and might have a regula-
tory role on estrogen-mediated cell proliferation in the repro-
ductive tract. 
Accordingly, this study examined the effects of HMGB-1
overexpression on the estrogen-induced cell cycle progression
in MCF-7 cells. 
MATERIALS AND METHODS
Expression plasmid constructs
The entire HMGB-1 (nucleotide positions +51-+744)
gene was amplified by PCR using the primers HMGB-1T
(for 5′ -tcgckgaggaaaawyaact-3′ ; rev 5′ -aaaactgcgctagaac-
caacttat-3′ ). PfuTurbo DNA polymerase (Stratagene, La Jolla,
CA, U.S.A.) was used for the PCR (conditions: 95℃, 1 min;
58℃, 45 sec; 72℃, 2 min for 30 cycles followed by 72℃,
10 min). The PCR products were cloned into the pGEM-T
easy vector (Promega, Madison, WI, U.S.A.) and sequenced
to confirm their identity. The HMGB-1 insert was also reclon-
ed into the pBluescript KS(+) gene (Stratagene). After restric-
tion enzyme digestion with Nhe I-Acc I, the DNA fragment
was cloned into the Xba I-Acc I digested pCIneo (Promega),
which yielded the plasmid HMGB-1-pCIneo. This plasmid
enabled the expression of the HMGB-1 gene under the con-
trol of the phage T7 promoter.
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Effects of HMGB-1 Overexpression on Cell-Cycle Progression in
MCF-7 Cells
High mobility group-1 (HMGB-1) enhances the DNA interactions and possesses a
transcriptional activation potential for several families of sequence-specific transcrip-
tional activators. In order to examine the effect of HMGB-1 on the cell cycle progres-
sion in MCF-7 cells, the HMGB-1 expression vector was transfected into synchronized
MCF-7 cells, and the effect of HMGB-1 overexpression on the cell cycle was exam-
ined. The HMGB-1 protein level in the transfected cells increased 4.87-fold compared
to the non-transfected cells. There were few changes in the cell cycle phase distri-
bution after HMGB-1 overexpression in the MCF-7 cells. Following the estrogen treat-
ment, the cell cycle progressed in both the HMGB-1 overexpressed MCF-7 and the
mock-treated cells. However, a larger proportion of HMGB-1 overexpressing MCF-7
cells progressed to the either S or G2 phase than the mock-treated cells. The mRNA
levels of the cell cycle regulators changed after being treated with estrogen in both
the HMGB-1 overexpressing MCF-7 and the mock-treated cells, but the changes
in the expression level of the cell cycle regulator genes were more prominent in the
HMGB-1 overexpressing MCF-7 cells than in the mock-treated cells. In conclusion,
HMGB-1 overexpression itself does not alter the MCF-7 cell cycle progression, but
the addition of estrogen to the HMGB-1 overexpressing MCF-7 cells appears to accel-
erate the cell cycle progression.
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Cell maintenance and Transfection
The MCF-7 cells were propagated in RPMI 1640 medium
(Gibco BRL, Paisley, U.K.) containing 100  g/mL gentam-
icin, 25 mM HEPES/NaOH, pH 7.3, and 10% heat-inacti-
vated fetal bovine serum (FCS, Gibco BRL) in a humidified
atmosphere of 5% CO2 at 37℃. Unless otherwise indicated,
all the experiments were performed using synchronized MCF-
7 cells. In order to synchronize the cultures, the MCF-7 cells
were harvested from the stock dishes and cultured in RPMI
supplemented with 10% FCS until they reached -50% con-
fluence. The cells were then washed with phosphate-buffered
saline (PBS) and cultured for 3 days in a RPMI 1640 phenol
red-free medium and 0.5% charcoal/dextran-treated FCS
(sFCS, HyClone, Logan, UT, U.S.A.). Under these conditions,
80 to 85% of the cells were arrested at the G0/G1 phase. 
In order to compare the cell cycle progression of the normal
MCF-7 cells and the HMGB-1 overexpressed MCF-7 cells,
the cells that were synchronized at the G0/G1 phase in the
60 mm dishes were transfected with HMGB-1-pCIneo and
pCIneo using the Lipofectamine Plus reagent (Gibco BRL)
according to the manufacturer’s instructions. After transfec-
tion, the cells were harvested for propidium iodide (PI, Sigma
Chemicals, St. Louis, MO, U.S.A.) staining.
The cells were then stimulated with 10 nM estrogen for
30 hr. The cells also harvested for PI staining at the comple-
tion of the experiments. 
Analysis of cell cycle kinetics
In order to analyze the cell cycle phase distribution, approx-
imately 1×106 cells were detached from the culture dishes
using trypsinization, diluted 1:1 in a complete medium, and
collected by low speed centrifugation at room temperature.
The cell pellet was resuspended in the 1 mL phosphate buf-
fered saline (PBS) containing 50  g PI (Sigma Chemicals),
and treated with 1  g of the RNases (Sigma Chemicals) for
30 min at 37℃. The samples were filtered through a 25-
gauge syringe needle immediately before undergoing flow
cytometry analysis.
Western Blot Analysis
The MCF-7 cells were homogenized and lysed in 0.5 mL
of the RIPA buffer (150 mM NaCl, 1% NP40, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0) with freshly
added 1 mM phenylmethylsulphonylfluoride (PMSF, Sigma)
for 30 min on ice. The lysates were centrifuged at 13,000 g
for 15 min at 4℃, and the supernatants were stored at -70℃
until needed. Equal amounts of the total protein (30  g) were
separated by SDS-PAGE, which were then transferred to a
supported westran PVDF (Schleicher & Schuell, New Hamp-
shire, U.S.A.) using 100 V-2 hr with a plate electrode appa-
ratus (Mini Trans-Blot Cell; Bio-Rad, CA, U.S.A.). The blots
were blocked for 2 hr in Tris-buffered saline (TBST, 0.2 M NaCl,
0.1% Tween-20, 10 mM Tris pH 7.4) containing 5% non-fat
dry milk. Subsequently, the blots were incubated with the anti-
bodies against HMGB-1 (1:1,000; BD Pharmingen 66741N)
in TBST, and then in anti-rabbit IgG (1:2,000; Amersham
Pharmacia Biotech, Freiburg, Germany) in TBST. After each
step, the blots were washed with TBST several times. The
bound antibodies were detected using an enhanced chemi-
luminescence (ECL) system (Amersham Pharmacia Biotech).
The blots were stripped with a stripping buffer (100 mM  -
mercaptoethanol, 2% (w/v) sodium dodecyl sulphate, 62.5
mM Tris-HCl pH 6.7) before applying the  -actin antibody.
The stripped blots were incubated with the  -actin antibodies
(1:2,000; for the internal standard, Sigma AC-15) in TBST
followed by anti-mouse IgG (1:2,000; Amersham Pharmacia
Biotech) in TBST.
RT-PCR
The total RNA was extracted from the MCF-7 cells using
a TRIzol reagent (Gibco-BRL) according to the manufacturer’s
instructions. The total RNA (2  g) was reverse transcribed
in a final 25  L Tris buffer (50 mM; pH 8.3) supplemented
with KCl (75 mM), MgCl2 (3 mM), DTT (5 mM), deoxynu-
cleotide triphosphate (0.5 mM, each, Gibco-BRL), oligo dT
(1.5  M), and Moloney murine leukemia virus (M-MLV)
reverse transcriptase (200 U, Promega) at 42℃ for 60 min.
PCR amplification was performed in a final 50  L reaction
volume containing 2  L of the reverse transcribed cDNA, 0.4
M of each primer, 1U of Taq DNA polymerase (Promega),
1×Taq DNA polymerase buffer, MgCl2 (2.5 mM), and deo-
xynucleotide triphosphate (0.2 mM each). The PCR reaction
was carried out using a Perkin Elmer DNA Thermal Cycler
(version 2.3) according to the following program; denaturing
for 1 min at 95℃, annealing for 45 sec at 55℃ (for Cyclin
D1), 61℃ (for Cyclin A), 66℃ (Cyclin B), 53℃ (for Cdk4)
and at 60℃ (for GAPDH), and elongation for 2 min at 74℃
for a total of 30 cycles (for Cyclin D1 and Cyclin B), 35 cycles
(for Cycln A and Cdk4), and 28 cycles (for GAPDH), except
for the final cycle, where the elongation step was extended to
10 min at 74℃. The amount of template cDNA used in each
reaction was normalized to the amount of GAPDH mRNA.
Amplification of the template cDNA was in the linear range
for the number of PCR cycles and RT-PCR of the GAPDH
transcript was performed using the same amount of cDNA
from each sample as a template. The PCR products were visu-
alized by electrophoresis on 1.5% (w/v) agarose gels.
Oligonucleotide primers
The Oligonucleotide PCR primers were selected with the
aid of a computer program (DNA STAR) designed to opti-
mize the GC content and melting temperature, and to min-
imize the level of hairpin and dimer formation. The PCRHMGB-1 Overexpression and Cell-Cycle Progression 323
primers were: Cyclin D1 forward 5′ -CCTACTCAAATGTGT-
GCAGAAG-3′ ; CyclinD1reverse5′ -CAAGGAGAATGAA-
GCTTT CCCTT-3′ ; Cyclin A forward 5′ -GCACCCCTTAA-
GGATCTTCC-3′ ; Cyclin A reverse 5′ -CCTCTCAGCACT-
GACATGGA-3′ ; Cycln B forword 5′ -CGGGAAGTCACTG-
GAAACAT-3′ ; Cyclin B reverse 5′ -CAGGTGCTGCATAA-
CTGGAA-3′ ; Cdk4 forword 5′ -CTTGC CAG CCGAAAC-
GAT-3′ ; Cdk4 reverse 5′ -CCACGGGGCAGGGATAC-3′ ;
GAPDH forward 5′ -ACCACAGTCCATGCCATCAC-3′ ;
GAPDH reverse 5′ -TCCACCACCC TGTTGC TGTA-3′ ,
which resulted in 887, 536, 567, 408 and 452 bp products,
respectively.
Densitometry
The gel image was scanned using a Gel Documentation
System (Gel Doc 1000, Bio-Rad, Hercules, CA, U.S.A.) and
the relative densities were analyzed using a Multi-analyst fin-
gerprinting program (version 1.1). The relative densities of the
bands are expressed in arbitrary absorbance units per unit area.
RESULTS
The primers were designed based on GenBank database in
order to include the entire HMGB-1 sequence. Six hundred
and ninety one-bp PCR products were cloned into the pGEM-
T easy vector and sequenced to confirm their identity (Fig.
1A). The HMGB-1 insert was then recloned into the pBlu-
script KS(+). After digestion with the restriction enzyme,
Nhe I-Acc I, the DNA fragment was cloned into pClneo/Xba I/
Acc I, in which the expression level of both the HMGB-1 and
neomycin resistant gene were controlled by a CMV promoter
(Fig. 1B). Finally, the plasmid containing the HMGB-1 was
transfected into the MCF-7 cells using the Lipofectamin Plus
reagent. Standard lines of MCF-7 human breast cancer cells
were used as the control in order to examine the transfection
efficiency. Western blot analysis was performed to analyze the
HMGB-1 expression level. The HMGB-1 level in the trans-
fected MCF-7 cells increased 4.87-fold compared to that in
the non-transfected cells (Fig. 2)
In order to establish a specific experimental system for ex-
amining the estrogen-regulated events regarding cell cycle
progression, the MCF-7 cells were synchronized at the G0/G1
phase by serum and estrogen deprivation, as described in
Materials and Methods. In the exponentially growing cells,
the proportion of cells in the G1, S, and G2+M phases were
66.74, 1.26 and 31.99%, respectively. After serum and estro-
gen deprivation for 3 days, the proportion of cells changed
to 80.88, 7.25 and 11.87%, respectively (Fig. 3A). In addi-
tion, this study examined whether or not the estrogen treat-
ment in the synchronized MCF-7 cells changed the HMGB-
1 mRNA level using RT-PCR. The HMGB-1 mRNA level
increased 1.6-fold 30 min after the estrogen treatment com-
pared to that of the basal level. The HMGB-1 mRNA level
then slightly decreased to 1.3-fold of the basal level after 45
min. This increased mRNA level was maintained through-
out the course of the estrogen treatment (data not shown). 
The cell cycle phase distribution was evaluated in the MCF-
7 cells using analytical DNA flow cytometry in order to deter-
mine if HMGB-1 affects the cell cycle progression. The MCF-
7 cells were transfected with HMGB-1 after synchronization
by serum and estrogen deprivation. HMGB-1 overexpression
did not alter the cell cycle progression compared to the mock-
treated cells (Fig. 3B, D). Estrogen was added to the synchro-
nized MCF-7 cells in order to analyze the effect of estrogen
on the cell cycle progression in the HMGB-1 overexpressed
MCF-7 cells and mock-treated cells. After the estrogen treat-
ment, there was few changes in the cell cycle phase distribu-
tion over the first 12 hr, but afterwards, the proportion of cells
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aaatgtcatc
HMGB-1T-forward primer
121 atatgcattt tttgtgcaaa cttgtcggga ggagcataag aagaagcacc cagatgcttc
181 agtcaacttc tcagagtttt ctaagaagtg ctcagagagg tggaagacca tgtctgctaa
241 agagaaagga aaatttgaag atatggcaaa agcggacaag gcccgttatg aaagagaaat
301 gaaaacctat atccctccca aaggggagac aaaaaagaag ttcaaggatc ccaatgcacc
361 caagaggcct ccttcggcct tcttcctctt ctgctctgag tatcgcccaa aaatcaaagg
421 agaacatcct ggcctgtcct ttggtgatgt tgcgaagaaa ctgggagaga tgtggaataa
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Fig. 1. Construction of the HMGB-1 vector. (A) The entire HMGB-1 (nucleotide +51-+744) sequences were based on the GenBank database.
Bold ATG was the start codon and TAA was the stop codon. The square box indicates the PCR primer. (B) The entire HMGB-1 was PCR
amplified using the primers HMGB-1T primer. PCR products were cloned into the pCIneo vector. 
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Fig. 2. Transfection efficiency of the HMGB-1 expression vector in the MCF-7 cells. MCF-7 cells synchronized at the G0/G1 phase were trans-
fected with 1  g HMGB-1 using the Lipofectamin Plus reagent. (A) After 2 days, the cell lysates were prepared and analyzed by immunoblotted
with HMGB-1 antisera. Mock -treated cells were used as the control. (B) The film was scanned with the Gel Doc. System and the relative den-
sities were analyzed. 
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Fig. 3. Kinetics of the cell cycle progression in the HMGB-1 overexpressing MCF-7 cells and the mock cells treated with or without estrogen.
The MCF-7 cells synchronized at the G0/G1 phase were transfected with HMGB-1, trypsinized, and treated with propidium iodide. The cell cycle
distribution was then analyzed by flow cytometry. (A) Before and after synchronization, the cell cycle distribution was analyzed by flow cytometry.
(B) Mock (C) Mock with estrogen (10e-7M). (D) HMGB-1 overexpressed MCF-7 cells. (E) HMGB-1 overexpressing MCF-7 cells with estrogen
(10e-7M). The results from two independent experiments are represented.
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Sin the G1 phase decreased from 62% to 52% after 16 hr in
the mock-treated cells, and from 62% to 49% after 16 hr in
the HMGB-1 overexpressed MCF-7 cells (Fig. 3C, E). This
decrease was accompanied by an increase in proportion of S
phase cells from 27% to 43% in the mock and from 27% to
47% in the HMGB-1 overexpressing MCF-7 cells, which is
a synchronized population of cells indicating the progression
from the G1 to S phase. The subsequent decline in the pro-
portion of S phase cells after 22 hr was accompanied by an
increase in the proportion of G2 phase cells from 6% to 18%
at 30 hr in the mock-treated cells and from 4% to 25% at 30 hr
in the HMGB-1 overexpressing MCF-7 cells. 
In order to confirm the molecular basis of this cell cycle
progression, an analysis of the gene expression level of the cell
cycle specific regulators was performed. For this, the total
RNA from the mock and HMGB-1 overexpressing MCF-7
cells were prepared at each time point and analyzed by RT-
PCR (Fig. 4). As expected, the mRNA levels of the S phase
progression marker (Cyclin A) as well as that of the G2/M
phase marker (Cyclin B) were not increased in the mock and
HMGB-1 overexpressing MCF-7 cells without estrogen (Fig.
4A, C). In contrast, the expression level of these mRNAs
changed after the estrogen treatment (Fig. 4B, D). After the
estrogen treatment, the Cyclin A mRNA levels increased
slowly over the first 16 hr and decreased dramatically after 22
hr in the HMGB-1 overexpressed MCF-7 cells. At that time
point, the Cyclin B mRNA levels also increased dramatically
(Fig. 4D). Similar patterns were observed in the mock-treated
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Fig. 4. mRNA levels of the cell cycle related genes in HMGB-1 overexpressing MCF-7 cells and mock cells treated with or without estrogen.
Mock and HMGB-1 overexpressed MCF-7 cells were seeded and treated with or without estrogen (10e-7M) as Fig. 3. At the indicated times,
the total RNAs were prepared and analyzed by RT-PCR. (A) Mock (B) Mock with estrogen (10e-7M) (C) HMGB-1 overexpressing MCF-7 cells
(D) HMGB-1 overexpressing MCF-7 cells with estrogen (10e-7M) (E) Bands of the RT-PCR product of the mock with estrogen (10e-7M) were
scanned and relative densities were analyzed (F). Bands of the RT-PCR products of HMGB-1 overexpressing MCF-7 cells with estrogen (10e-
7M) were scanned and the relative densities were analyzed.
0 3 6 9 12 16 22 30 hr
Cyclin D1
Cyclin A
Cyclin B
Cdk4
GAPDH A
0 3 6 9 12 16 22 30 hr
Cyclin D1
Cyclin A
Cyclin B
Cdk4
GAPDH B
0 3 6 9 12 16 22 30 hr
Cyclin D1
Cyclin A
Cyclin B
Cdk4
GAPDH C
0 3 6 9 12 16 22 30 hr
Cyclin D1
Cyclin A
Cyclin B
Cdk4
GAPDH D
R
e
l
a
t
e
d
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
 
(
%
)
Time after transfection (hr)
HMGB-1 overexpressed MCF-7 cells with Estrogen
100
80
60
40
20
0
0 3 6 9 12 16 22 30
F
Cyclin D1
Cyclin A
Cyclin B
Cdk4
Cyclin D1
Cyclin A
Cyclin B
Cdk4cells with estrogen. However, the changes in the mRNA levels
were more prominent in the HMGB-1 overexpressing MCF-
7 cells than in the mock-treated cells (Fig. 4B). The mRNA
levels of the G1 phase marker (Cdk4 and Cyclin D1) did not
change remarkably.
DISCUSSION
HMGB-1 enhances the DNA interactions and has the po-
tential to activate the transcription of several different families
of sequence-specific transcriptional activators (10). Because
HMGB-1 is a conserved, ubiquitous protein, it might func-
tion as a general cofactor for a wide range of transcriptional
activators. In particular, HMGB-1 is believed to influence the
steroid hormone class of the nuclear receptors, and has no
effect on the DNA binding of the transactivation function
of the class II nuclear receptors (1). It was reported that the
HMGB-1 expression level increased in the estrogen respon-
sive breast cancer cells treated with estrogen (7). In this study
the MCF-7 cells that expressed ER responded to an estrogen
treatment with a rapid increase in the HMGB-1 mRNA level,
which is in accordance with the results reported by Chau et
al. (7). Therefore, the transcription activation of the estrogen
responsive genes by estrogen may require HMGB-1 produc-
tion. A study on the regulation of HMGB-1 suggested that
two potential estrogen responsive elements (ERE) in intron
1 of the HMGB-1 gene might be involved in the estrogen-
dependent transcription (11). 
HMGB-1 was transfected into the synchronized MCF-7
cells in order to examine the effect of HMGB-1 on cell cycle
progression. Prior to transfection, 80.88% of the MCF-7 cells
were synchronized at the G0/G1 phase. However, after trans-
fection, only 60% of the cells were in the G0/G1 phase. It is
possible that the Lipofectamin Plus reagent caused this dis-
crepancy. When compared to the mock-treated cells, HMGB-
1 overexpression did not alter the cell cycle progression. Fol-
lowing the estrogen treatment, the cell cycle progressed in
both the HMGB-1 overexpressed MCF-7 and mock-treated
cells. In contrast to Prall et al. (12) the cell cycle phase dis-
tribution did not change dramatically after the estrogen treat-
ment in the mock-treated cells. Nevertheless, the progression
from the G1 to S phase and then to the G2 phase was more
prominent in the HMGB-1 overexpressing MCF-7 cells than
the mock-treated cells. This suggests that HMGB-1 play a
role in the estrogen dependent cell cycle progression. The cell
cycle regulator genes were also altered after the estrogen treat-
ment in both the HMGB-1 overexpressing MCF-7 cells and
the mock-treated cells. However, the mRNA levels of cell
cycle regulators changed more dramatically in the HMGB-1
overexpressing MCF-7 cells than the mock-treated cells.
In conclusion, HMGB-1 overexpression itself does not alter
the MCF-7 cell cycle progression, but the cell cycle progres-
sion appears to be accelerated by addition of estrogen to the
HMGB-1 overexpressing MCF-7 cell.
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